Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 31096 matches for

New research from Dr Richard Williams’ group at the Kennedy Institute suggests a route for the development of more selective – and effective – therapies for immune-mediated inflammatory disease.

Artists representation of T lymphoyctes. Signalling through TNFR2 receptor maintains Foxp3 expression in suppressor T lymphocytes.

Oxford Trauma

Study with us

Research groups

Clinical Kennedy Trust Prize Studentships

Applications for these projects close at noon on Friday 2 December 2025.

Botnar projects

Applications for these projects close at noon on Friday 2 December 2025.

Events

About us

Trials

OPEN ARMS

SITU

Jobs

Trials in closure

Trials in follow up

Trials under analysis

Trials open to recruitment

Trials in set-up

Themes

OCTRU runs trials across multiple areas of medicine. Within OCTRU there are five core therapeutic areas of expertise, although trials are also undertaken outside of these areas and groups.

Our studies

Lymphocyte Antigen Receptor Signaling Workshop

Information Security Policy

Load More

Meet the team

TNF receptor 2 signaling prevents DNA methylation at the Foxp3 promoter and prevents pathogenic conversion of regulatory T cells

Read the paper

Find out more about

Similar stories